Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

mRNA Vaccine Against Japanese Encephalitis Virus Genotype IV Protects Against Lethal Infection.

Viruses·2026
Same author

CD56<sup>bright</sup>NK cells are negatively associated with antibody response to vaccination in people with multiple sclerosis on B-cell-depleting therapy.

Clinical & translational immunology·2026
Same author

Multi-antigen DNA vaccine targeting non-structural proteins confers robust T Cell-mediated protection against Zika virus.

NPJ vaccines·2026
Same author

Evidence from COVID-19 Patients and Murine Studies for a Continuing Trend Towards Targeting of Nasopharyngeal Ciliated Epithelial Cells by SARS-CoV-2 Omicron Sublineages.

Viruses·2025
Same author

Vaccine-Induced and Hybrid Immunity Against SARS-CoV-2 Variants of Concern in Two Cohorts in Queensland, Australia (2021-2022).

Journal of medical virology·2025
Same author

Development and proof-of-concept evaluation for a low resource compatible Chikungunya virus diagnostic.

PLoS neglected tropical diseases·2025

Related Experiment Video

Updated: Apr 15, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

10.9K

Engineering human rhinovirus serotype-A1 as a vaccine vector.

Khamis Tomusange1, Wenbo Yu1, Andreas Suhrbier2

  • 1Virology Laboratory, Basil Hetzel Institute, Discipline of Surgery, University of Adelaide, Adelaide, South Australia, Australia.

Virus Research
|April 15, 2015
PubMed
Summary

Researchers created stable recombinant human rhinoviruses (rHRVs) to carry HIV genes for potential vaccine development. These engineered viruses successfully maintained the inserted genetic material, paving the way for mucosal immunity strategies.

Keywords:
HIV GagHIV TatHuman rhinovirus A1Vaccine vector

More Related Videos

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

23.0K
Generating Recombinant Avian Herpesvirus Vectors with CRISPR/Cas9 Gene Editing
12:21

Generating Recombinant Avian Herpesvirus Vectors with CRISPR/Cas9 Gene Editing

Published on: January 7, 2019

14.4K

Related Experiment Videos

Last Updated: Apr 15, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

10.9K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

23.0K
Generating Recombinant Avian Herpesvirus Vectors with CRISPR/Cas9 Gene Editing
12:21

Generating Recombinant Avian Herpesvirus Vectors with CRISPR/Cas9 Gene Editing

Published on: January 7, 2019

14.4K

Area of Science:

  • Virology and Molecular Biology
  • Vaccine Vector Development
  • Immunology

Background:

  • Human rhinoviruses (HRVs) are common viruses.
  • Recombinant viral vectors are explored for vaccine delivery.
  • HIV gene delivery presents a significant public health challenge.

Purpose of the Study:

  • To construct recombinant human rhinoviruses (rHRVs) capable of encoding HIV Gag or Tat proteins.
  • To assess the stability and utility of these rHRVs as potential vaccine vectors for mucosal immunity.

Main Methods:

  • Insertion of full-length HIV tat gene or gag gene regions into the HRV genome.
  • Utilized HRV 2A protease cleavage sites flanking the inserted genetic material.
  • Modified flanking cleavage sites to enhance recombinant construct stability through multiple passages.

Main Results:

  • Initial rHRV constructs were unstable, but instability was overcome by mutating flanking cleavage sites.
  • All modified rHRV constructs demonstrated stability, retaining inserted HIV genes through six passages.
  • Demonstrated successful incorporation and retention of foreign genetic material within the HRV vector.

Conclusions:

  • Engineered rHRVs can stably carry and express HIV genes.
  • Modified cleavage sites are crucial for maintaining the integrity of recombinant viral vectors.
  • These stable rHRV constructs show promise as vaccine vectors for inducing mucosal immunity against HIV.